Date published: 2026-2-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

AGP-8 Inhibitors

Chemical inhibitors of AGP-8 include a diverse group of compounds that interfere with the protein's function through several distinct mechanisms. Staurosporine and Imatinib, for example, can inhibit AGP-8 by targeting its possible kinase activity. These inhibitors block the ATP binding site of AGP-8, thus preventing any phosphorylation activity that AGP-8 may be involved in. Specifically, Imatinib binds to the tyrosine kinase domain, which would impede AGP-8 if it operates within that capacity. Similarly, LY294002 and Wortmannin can inhibit AGP-8 by obstructing the PI3K/Akt pathway, which is critical for multiple cellular functions. These inhibitors impede the formation of PIP3, a vital secondary messenger in the PI3K pathway, potentially reducing AGP-8 activity that is contingent on this signaling cascade.

Additionally, PD98059 and U0126 serve as inhibitors of the MAPK/ERK pathway, which could be a signaling pathway where AGP-8 has a role. By inhibiting the upstream kinases MEK1 and MEK2, these chemicals prevent the activation of the ERK pathway, which can limit AGP-8's functionality tied to this signaling route. SB203580 and SP600125 are inhibitors targeting the p38 MAPK and JNK pathways, respectively, which are pathways that AGP-8 may be involved in, particularly in cellular responses to stress or cytokines. The inhibition of these pathways can hinder AGP-8's activity in cells by preventing necessary signaling events from occurring. Proteasome inhibitors MG132 and Bortezomib can inhibit AGP-8 by preventing the degradation of regulatory proteins that are responsible for controlling AGP-8's function. This results in the accumulation of such regulatory proteins and indirect inhibition of AGP-8's activity. Lastly, Rapamycin and Trichostatin A act on mTOR signaling and chromatin structure, respectively. Rapamycin inhibits mTOR complexes that AGP-8 may need for activation, while Trichostatin A can alter gene expression patterns of proteins that regulate AGP-8, both leading to functional inhibition of AGP-8.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

Staurosporine is a potent kinase inhibitor that can inhibit AGP-8 if the protein has kinase activity, by blocking its ATP-binding site, thus preventing phosphorylation processes AGP-8 might be involved in.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is a PI3K inhibitor that, if AGP-8 is part of PI3K/Akt signaling, can inhibit AGP-8's function by preventing the production of PIP3, which is necessary for AGP-8 associated pathway activation.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is an ERK pathway inhibitor that may inhibit AGP-8 by blocking the MAPK/ERK pathway, which could be upstream or downstream of AGP-8 function, thus preventing AGP-8 related signaling.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a p38 MAPK inhibitor that potentially inhibits AGP-8 by disrupting the p38 MAPK pathway related to stress responses that AGP-8 could be a part of, hindering AGP-8's functional role.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$60.00
$265.00
$1000.00
163
(3)

MG132 is a proteasome inhibitor that can inhibit AGP-8 by preventing the degradation of regulatory proteins that control AGP-8 function, leading to the accumulation of such regulatory proteins and indirect inhibition of AGP-8.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Bortezomib, another proteasome inhibitor, can inhibit AGP-8 by similar mechanisms as MG132, potentially leading to altered signaling dynamics that could suppress AGP-8 activity.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin is an mTOR inhibitor that can indirectly inhibit AGP-8 if it's part of the mTOR signaling pathway by inhibiting mTORC1 and possibly mTORC2 complexes, which may be required for AGP-8 functional activity.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$67.00
$223.00
$425.00
97
(3)

Wortmannin, like LY294002, is a PI3K inhibitor that can prevent the phosphorylation and activation of AGP-8 if it's involved in the PI3K/Akt pathway, leading to functional inhibition.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is a JNK inhibitor that can inhibit AGP-8 by blocking the JNK signaling pathway, which could be essential for AGP-8's role in cellular responses to stress or cytokines.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Imatinib is a tyrosine kinase inhibitor that can inhibit AGP-8 if the protein has tyrosine kinase activity or is part of a pathway regulated by tyrosine kinases, by preventing phosphorylation of the protein or its substrates.